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ABSTRACT 
Objective: This study was proposed to evaluate and compare the in vitro dissolution profiles of six Metformin Hydrochloride (MH) market products. 
Methods: Different dissolution apparatuses (USP apparatus II, IV and beaker method) were used to evaluate the dissolution profiles (in phosphate 
buffer, pH 6.8) of two immediate release (IR) generic products of Metformin Hydrochloride (MH): Cidophage® 1000 mg (G1, Egyptian market) and 
Metformin arrow® 1000 mg (G2, French market) with respect to the reference products named Glucophage® 850 mg (R1, Egyptian market and R2, 
French market). In addition to a generic controlled-release (CR) product; Cidophage Retard® 850 mg (G3) versus the reference product; 
Glucophage XR® 1000 mg (R3) (both from Egyptian market). Dissolution efficiency (D. E.) and the similarity factor (f2) were calculated. Weight 
uniformity, hardness, tablet dimensions and MH content were measured.  
Results: Results of the three apparatuses showed that MH IR products studied (reference and generics) did not meet the 75% USP 30 specifications 
for MH dissolved at 30 min. For MH CR products, Glucophage XR® did not fulfill the USP release criteria, while Cidophage Retard® did. USP 
apparatus IV revealed the highest sensitivity and discriminative capability.  
Conclusion: Generally, MH IR generics (G1 and G2) might be interchangeable with the innovator product (Glucophage®). However, Cidophage 
Retard® might not be interchangeable with Glucophage XR®. 
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For many years, efforts have been made to minimize the number of 
in vivo studies required to approve a new molecule or a generic 
product. One of the approaches currently used is the in vitro (mainly 
dissolution) tests that act as a tool to predict drug product 
performance in vivo [1-4]. It is necessary to have precise and 
reproducible dissolution data resulting from physiochemically and 
hydrodynamically determined conditions to compare variability and 
reproducibility for in vitro dissolution data and to manage using 
such results as a replacement for in vivo bioavailability, 
bioequivalence testing and in vitro/in vivo correlations (IVIVC) [5]. 
Dissolution testing is empirical in vitro laboratory performance test 
that judges how a drug is released from its dosage form efficiently. 
During drug development, dissolution profiles have been utilized to 
comprehend the influence of formulation composition on the in vitro 
release of an active pharmaceutical ingredient (API). It plays as well 
an important role in the context of science and risk-based process 
development, validation and evaluation of post-approval 
formulation changes to drug product quality [6].  
Also, after product development, in vitro dissolution is an important 
test in QC to ensure batch to batch consistency, to establish shelf life 
during stability studies [7] and to predict in vivo performance (i.e. 
bioavailability) [2].  
Although the Flow through the cell (FTC) became an official USP 
method since 1995 (USP Apparatus IV) [8], in vitro dissolution studies 
using this apparatus under different operational conditions and/or 
features are few in literature [5, 9-17]. Our previous studies using the 
FTC proved that we should optimize the in vitro dissolution conditions 
for the finished product or during the preparation of different 
formulations to achieve accurate and reproducible results and to 
detect the effect of minor formulation changes upon storage [18]. 
Metformin, 1,1-dimethyl biguanide, has properties of a strong base 
(pKa, 11.5) (log P, −1.43). Metformin hydrochloride (MH) is a salt of 
a strong base and a strong acid so it is completely ionized in the 
physiological pH [19]. MH is considered the first-line treatment 
according to international guidelines for patients with (T2DM). It 
belongs to a class of drugs known as the biguanides. Bioavailability 
of MH, when given orally, is 50–60% and it's the biological half-life 
of is 1.5–4.5 h and its main site of absorption is proximal small 
intestine. Chemically, MH is freely soluble in water and is classified 
as class III according to the Biopharmaceutical Classification System 
(BCS) with high solubility and low permeability [20-23].  
Currently, MH is available in the market as immediate-release (IR) and 
controlled release (CR) dosage forms. Glucophage® is the innovator 
product that stands out in terms of quality and efficacy, but because of 
the high price associated with some branded products, some patients 
and governments may be biased to go for generic products [24]. 
Although the active ingredient is synonymous in both generic and brand 
name drug, evidence proves that there are definite differences in their 
therapeutic effects [25]. This may be due to differences in rate and extent 
of absorption [26], excipients and manufacturing processes [27] or the 
manufacturing variables such as the mixing effect and granulation 
procedure [7]. Few studies compared the performance of innovator and 
generic products of MH in different countries [26, 28-35]. 
Till now, there are 13 dissolution methods in the U. S. Pharmacopeia 
[36] for MH tablets to describe its release profile utilizing either 
apparatus I or apparatus II at 100 rpm and 1000 ml of phosphate 
buffer solution (pH 6.8) as dissolution medium. Nevertheless, it is 
still valuable to investigate the in vitro dissolution performance of 
MH tablets employing USP apparatus IV versus USP apparatus II 
based on its numerous merits.  
Therefore, the focus of this study was to evaluate an in vitro 
dissolution method for MH, using the flow-through cell apparatus 
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(USP apparatus IV) and beaker method (non-official method 
simulating the USP paddle method) compared to the pharmacopeial 
USP apparatus II method. This will be carried out on MH tablet 
products available in the Egyptian and European market. 
MATERIALS AND METHODS 
Materials 
Pure metformin hydrochloride (MH) was kindly donated from 
Sigma, Cairo, Egypt. MH products evaluated were immediate and 
controlled release tablets (850 mg or 1000 mg MH/tablet) 
purchased from the Egyptian and European markets. All tests were 
performed within the products expiration date. 
Investigated IR products were: two reference products with the 
same trade namely: R1-Glucophage® 850 mg tablets, Merk Serono, 
France (purchased from a retail pharmacy in Cairo, Egypt) (batch 
number 110017); R2-Glucophage® 850 mg tablets, Merk Serono, 
France (purchased from country representative) (LOT number 
F5503). Two generic products: G1-Cidophage® 1000 mg tablets, 
CID, Egypt (batch number 01140534); G2-Metformin arrow® 
1000 mg tablets, Arrow Generiques, France (LOT number 1297). 
Investigated CR products: reference product; R3-Glucophage 
XR® 1000 mg tablets, Merk serono, Germany (purchased from a 
retail pharmacy in Cairo, Egypt) (batch number 171521) and 
Generic product; G3-Cidophage Retard® 850 mg tablets, CID, 
Egypt (batch number 03140848).  
Sodium hydroxide pellets and Potassium dihydrogen ortho-
phosphate were purchased from ADWIC, Egypt. Methanol (HPLC 
grade, TEDIA, USA) was used for stock solution preparation. 
Milli-RO purified water (Millipore Corp., Billerica, MA, USA) was 
used to prepare the dissolution medium. 
Methods 
Analysis of MH 
A standard curve ranging from 0.5 to 10 μg/ml in phosphate buffer 
(pH 6.8) was constructed. A stock solution was prepared by 
dissolving 5 mg of MH powder in 50 ml methanol to yield a 
concentration of 100 μg/ml. This solution was serially diluted with 
phosphate buffer (pH 6.8) to yield the desired concentration range. 
The absorbance of the prepared solutions was measured 
spectrophotometrically (DU–650 UV-Vis spectrophotometer, 
Beckman, USA) at predetermined λmax of 231 nm against the 
phosphate buffer (pH 6.8) as blank. Absorbance was plotted against 
MH concentration and the response factor was calculated. Each 
concentration was analyzed in triplicate and the mean values were 
calculated. A linear zero-intercept relationship was established, 
where the slope and regression coefficient were 0.1026 and 1, 
respectively. Percent recoveries ranged from 94.02% to 100.37%, 
and the average response factor was 9.865±0.254. 
Tablet characteristics 
Uniformity of weight 
Twenty tablets of each MH product were weighed individually and 
the weight variation was calculated using Microsoft Excel 2010.  
Physical parameters 
Tablet Hardness Tester [MT 50 3 in 1 Hardness, Diameter and 
Thickness Tester (Sotax-MT 50 MultiTest 50, Switzerland)] was 
used for determination of tablet dimensions and hardness of the 
tested brands (mean of twenty tablets for each product was 
calculated). 
Content uniformity 
Twenty tablets of each product were weighed, ground and the 
weight equivalent to one tablet was transferred quantitatively into 
100 ml volumetric flask. About 70 ml of water was added to each 
flask and then shaked for 15 min using "temperature-controlled 
shaking water-bath" (Lab-Line, USA) at 37 °C. The final volume was 
adjusted with water followed by mixing. The solution was then 
filtered and appropriate dilutions were done to the filtrate using 
water. The absorbance was then measured spectrophotometrically 
(UV-Visible spectrophotometer, Beckman, DU-650, USA) at the 
predetermined λmax at 231 nm for MH [37]. 
Comparative in vitro dissolution study of MH products 
USP apparatus II (pharmacopeial method) 
For such studies, MH products were examined utilizing USP 
apparatus II (AT8-Xtend, Sotax, Switzerland) at a rotational speed of 
100 rpm at 37.0±0.5 °C in 900 ml phosphate buffer (pH 6.8) (fig. 1A). 
Each dissolution study was done on six tablets. Samples were drawn 
manually. Each sample was replaced with an equal amount of blank 
buffer at 37 °C. Samples were then filtered through a syringe filter 
with a pore size of 0.45 μm and a diameter of 25 mm. Dissolution 
samples were analyzed spectrophotometrically (DU–650 UV-Vis 
spectrophotometer, Beckman, USA) at predetermined λmax of 231 nm 
against the blank.   
Flow-through cell apparatus (USP apparatus IV) 
The comparative in vitro dissolution studies of marketed MH 
products, were carried out using the closed-loop setup of FTC [USP 
Apparatus IV, a Dissotest CE-6 equipped with a CY 7-50 piston pump 
(Sotax, Switzerland)]. Each tablet was placed into the large 
dissolution cell (22.6 mm diameter). A built-in filtration system with 
0.7-μm Whatman glass micro-fiber (GF/F and GF/D) and glass wool 
were used throughout the study (fig. 1B). The dissolution medium 
was filtered degassed phosphate buffer (pH 6.8) maintained at 
37.0±0.5 °C and pumped at 8±0.2 ml/min. The dissolution studies 
were carried out on six tablets. Sample fractions were collected at 
the following time intervals: 5, 10, 15, 20, 25, 30, 45, 60 and 75 min 
for IR products and for appropriate fractions for up to 6 h for CR 
products. The fractions were analyzed by UV/spectrophotometric 
method at 231 nm against phosphate buffer (pH 6.8) as blank. 
Beaker method 
For the beaker method, the set up consisted of 1L jacketed beakers 
connected to refrigerated circulator apparatus (julabo circulators 
F10-VC, Germany). Each beaker was filled with 900 ml phosphate 
buffer (pH 6.8) maintained at 37.0±0.5 °C. A constant stirring rate 
was maintained in each beaker using a magnetic stirrer with the 
magnet kept below a stainless steel mesh (fixed height = 1.5 cm) 
placed at the bottom of each beaker (fig. 1C). Samples fractions were 
collected at specified time intervals for a total of 75 min for IR 
products and 6 h for CR products. The amount dissolved of MH was 
determined spectrophotometrically as described previously. All 
experiments were done on six tablets. 
Statistical analysis of in vitro dissolution data 
Similarity factor (f2) 
The dissolution profiles of different MH IR and CR market products 
were compared with the reference product in different apparatuses 
using similarity factor (f2) as proposed by Moore and Flanner [38] 
which is defined as follows (Equation 1):  
f2 = 50 log 1 + 1 n  	 wt(Rt − Tt)2n
t1
0.5 × 100  Equation (1) 
Where Rt is the percentage of released drug for a reference batch at 
time point t, Tt is the percentage of released drug for the test batch, n 
is the number of pull points collected during the in vitro release test, 
Rt and Tt are the cumulative percentages release at the selected time 
point of the two tested formulae. FDA has set a public standard of ƒ2 
value of 50-100 to indicate similarity between two dissolution 
profiles [39]. 
Dissolution efficiency 
Khan and Rhodes [40] used the trapezoidal rule to calculate the area 
under the dissolution curve at the time (t) to obtain the dissolution 
efficiency (D. E.) expressed as a percentage of the area of the rectangle 
described by 100% dissolution in the same time [41]. (D. E.) is defined 
as follows:  
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D. E =   ydtt0
y
100
× t × 100 Equation (2) 
RESULTS AND DISCUSSION  
All MH tablets of the six products under investigation showed 
acceptable tablet characteristics regarding weight variation, physical 
parameters and content uniformity, as shown in table 1. 
 
 
Fig. 1: Schematic diagrams of: (A) USP apparatus II, (B) USP apparatus IV, (C) Beaker method 
 
Table 1: Evaluated physicochemical properties of the six MH market products 
















Glucophage® 850mg,  Egyptian market (R1). Round 904±6.6 320±13.8   6.5± 0.01 13.5± 0.02 98.4± 0.5 
Glucophage® 850mg, French market (R2). Round 901±6.1 281±4.1   6.5± 0.1 13.5± 0.01 99.9± 0.4 
Cidophage® 1000 mg  Oblong 1071±8.2 628±15.1 9± 0.2 20±0.1 6.32± 0.2  98.6± 1 
Metformin arrow® 1000 mg (G2). Oblong 1108±3.6 443±17.6 8.7±0.01 21.9±0.2 7.3±0.01  95.4± 0.6 
Glucophage XR® 1000 mg (R3).  Oblong 1441±8.8 141±3.7 10.6± 0.1 22.12±0.01 8.2± 0.1   95± 0.4 
Cidophage Retard® 850 mg (G3).  Round 899±7.8 182±16.8     6.4± 0.02 13.4± 0.01 95.3± 2 
*P. C: Product Code, L. N: Lot Number, **All values expressed as mean±SD, where n=20 
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Fig. 2: Dissolution profiles of four MH IR products obtained using: (A) USP apparatus II, (B) USP apparatus IV, and (C) Beaker method 
(mean±SD, n = 3) 
 
Comparative in vitro dissolution study of MH IR products 
The results of the dissolution experiments carried out in USP 
apparatuses II, IV and the beaker are presented in (fig. 2: A-C). In the 
case of USP apparatus II and beaker method, the dissolution behavior 
of generic products G1 and G2 compared with reference products R1 
and R2 were almost identical. On the other hand, dissolution 
differences were detected upon applying USP Apparatus IV. 
The calculated f2 values are presented in fig. 3 to compare MH 
dissolution profiles of R2, G1 and G2 versus R1: Glucophage® 850 
mg (Egyptian market). D. E. was also calculated, table 2 lists the 
corresponding results obtained for the difference of the mean D. E. 
(D. D. E.) and the difference in confidence intervals (D. C. I.). If the 
differences of the mean D. E. and the 95% C. I. are within limits 
(±10%), it can be concluded that the dissolution profiles of the 
reference and test are equivalent [41]. 
  
 
Fig. 3: Comparison between dissolution profiles of different MH IR market products (R2, G1, G2) versus R1 (Glucophage®) expressed by 
the similarity factor "ƒ2", utilizing different apparatuses (mean±SD, n = 3) 
 
USP apparatus II  
The dissolution profiles of R2, G1 and G2 were compared to that of 
the innovator product R1. It was found that the two parameters of D. 
E. (D. D. E. and D. C. I.) were accepted for R2: Glucophage® 850 mg 
(French market), but for the generics Cidophage® (G1) and 
Metformin arrow® (G2), D. C. I. was out of range. Thereby, the two 
products named Glucophage® (R1 and R2) had a similar dissolution 
profile in terms of D. C. I., D. D. E. (table 2) and f2 (fig. 3), while G1 
and G2 declared dissimilar dissolution profiles when compared to 
R1 only in terms of D. C. I. Meanwhile, they all revealed similar 
dissolution profiles in terms of f2 (fig. 3) and D. D. E (table 2). The Q30 
min values were 66.3%, 62.7%, 66.2% and 58.7% for R1, R2, G1, and 
G2, respectively. Thus, we can conclude that USP apparatus II could 
hardly detect differences in dissolution profiles of the tested MH IR 
products.
  
Table 2: Mean dissolution efficiencies (D. E.) with 95% confidence intervals (C. I.) calculated from in vitro release data of MH IR tablets 
Apparatus Tested product Product code Mean D. E. (%) with C. I. D. D. E. D. C. I. 
USP II Glucophage® 850 mg, Egyptian market R1 54.65 (50.84, 58.46) 0 0 
Glucophage® 850 mg, French market R2 58.85 (54.21, 63.48) -4.2 4.25 
Cidophage® 1000 mg  G1 55.09 (48.72,61.45) -0.44 9.74 
Emara et al. 
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Metformin arrow® 1000 mg G2 55.84 (51.33, 60.35) -1.19 7.13 
USP IV Glucophage® 850 mg, Egyptian market R1  51.76 (45,65.52) 0 0 
Glucophage® 850 mg, French market R2 57.62 (49.22,66.02) -5.86 16.3 
Cidophage® 1000 mg  G1 57.86 (54.73,60.99) -6.1 10.79 
Metformin arrow® 1000 mg G2 44 (17.66, 70.39) 7.76 47.86 
Beaker method Glucophage® 850 mg, Egyptian market R1 46.47 (40.56, 52.38) 0 0 
Glucophage® 850 mg, French market R2 48.74 (41.63, 55.85) -2.27 10.75 
Cidophage® 1000 mg  G1 43.92 (43.75, 44.10) 2.55 8.63 
Metformin arrow® 1000 mg G2 49.56 (43.65, 55.47) -3.09 8.73 
*D. E.: Dissolution Efficiency, C. I.: Confidence Intervals, D. D. E.: Difference of the mean D. E. between the innovator and the tested product, D. C. I.: 
Difference in confidence intervals and is calculated by considering the maximum possible mean D. E. value of Innovator and minimum possible 
mean D. E. value of other products (mean±SD, n = 3). 
 
Other researchers studied the commercially available MH IR 
products using USP apparatus II. Olusola et al. [28] compared the 
dissolution rate of eight commercially available MH tablets in 
Nigeria and found that only four brands could be considered as bio-
pharmaceutically and chemically equivalent. Sougi et al. [34] 
conducted a study for evaluation of fifteen MH IR commercial brands 
in Ghana and concluded that not all the commercial brands of MH 
tablets had similar dissolution profiles as the innovator depending 
on the ƒ2 analysis. Previously, a study done by Hamdan and Jaber 
[42] on five brands of MH in Jordanian market declared that four out 
of five brands were not equivalent to innovator brand except for one 
that is equivalent to an innovator in terms of ƒ2 analysis of the 
dissolution profiles. Moreover, another study was done on five IR 
brands of MH in the Saudian market, which also revealed that all the 
brands, except one, were non-equivalent to innovator Glucophage 
product [33]. 
USP apparatus IV  
Dissolution performance of MH IR products in USP apparatus IV is 
illustrated in fig. 2(B). The Q30 min results were 47.6%, 69.3%, 61.8% 
and 40% for R1, R2, G1, and G2, respectively. Fig. 2 clarified that USP 
apparatus IV was the dissolution apparatus that revealed the highest 
sensitivity and discriminative capability in differentiating between 
the dissolution behavior of MH products than USP apparatus II and 
beaker method. Similar observations were reported by Hurtado y de 
la Peña et al. [43] who highlighted by statistical analysis the 
discriminative capability of USP apparatus IV versus USP apparatus 
II in differentiating the release characteristics of tested albendazole 
products.  
Fig. 3 shows a comparison between dissolution profiles of different 
MH IR market products (R2, G1, G2) versus R1 (Glucophage®) 
expressed by similarity factor "ƒ2", utilizing different apparatuses 
while table 2 shows the mean dissolution efficiencies (D. E.) with 
95% confidence intervals (C. I.) calculated from in vitro release data 
of MH IR tablets. According to fig. 3 and table 2, USP apparatus IV 
revealed that the two innovator products (R1 and R2), named 
Glucophage, (from Egyptian and French markets) have dissimilar 
dissolution profiles in terms of f2 (48), D. D. E. (-5.86) and D. C. I. 
(16.3±10%).  
The dissolution profiles of the two generic MH IR products (G1, G2) 
were compared with the innovator R1 using f2 (fig. 3) and D. E. (table 
2). f2 values were 54 and 55 for G1 and G2, respectively indicating 
similar dissolution profiles (fig. 3). However, upon comparing the 
dissolution efficiency of these two generic MH products with respect 
to the innovator R1, it was found that D. D. E values (-6.1 and 7.76 
for G1 and G2, respectively) and D. C. I. values (10.79 and 47.86 for 
G1and G2, respectively) were out of range (table 2) which indicated 
dissolution dissimilarity between G1 and G2 versus innovator R1 
under these operational conditions. 
In case of R1 and R2, our results that show dissolution dissimilarity 
is in consistence with Stuart et al. [31] who assumed that the two 
MH innovator products having similar trade name (Glucophage), but 
came from different manufacturers, were statistically different 
regarding their dissolution profiles. Likewise, Crison et al. [44] 
stated that MH IR tablets obtained from different markets showed 
diverse drug release profiles. Moreover, in a previous study done 
using USP apparatus IV [12], the authors concluded that two tested 
reference products of diclofenac sodium tablets (Voltaren 100 mg) 
manufactured in different manufacturing sites (Novartis-Egypt, 
Novartis-Switzerland), displayed notable differences in the release 
rate of diclofenac sodium. In this respect, the two products might 
give different in vivo data [45]. 
The perceived variations between results obtained from USP 
apparatus II and IV can be explained due to differences in the 
hydrodynamic conditions that characterize this system. Medina et al. 
[46] reported a comparative in vitro dissolution study of 
carbamazepine immediate-release products using the USP apparatus 
II method and the flow-through cell apparatus and concluded that all 
products showed a slower dissolution rate in USP apparatus IV than 
the one found with the USP paddle method. Langenbucher et al. [48] 
clarified that kind of behavior to be related to the hydrodynamic 
conditions that illustrate the flow-through cell apparatus, where no 
agitation mechanisms exist so the dosage form is exposed to a 
uniform flow, like the surroundings of the GIT, producing different 
dissolution pattern.  
The hypothesis of the effect of variable hydrodynamics on drug 
dissolution came to be verified by McCarthy et al. [49] depending on 
a high-performance computing software system to simulate the USP 
dissolution apparatus II (paddle apparatus) to characterize the fluid 
hydrodynamics in the method. Similarly, Computational analysis 
was used to examine the hydrodynamic environment within USP 
apparatus II at common operating conditions by Kukura et al. Their 
results showed that the uneven distribution of hydrodynamic forces 
in USP apparatus II is a direct cause of dissolution testing variability 
[50]. 
Beaker method  
The dissolution profiles of the four MH IR tested products obtained 
using the beaker method are plotted in fig. 2(C). R1, R2, and G1 
apparently showed slower dissolution rates in beaker method than 
in other apparatuses in terms of Q30 min; the values were 46.7%, 
45.8%, 42.8% for R1, R2 and G1, respectively. But for G2, Q30 min 
(44%) was close to that of USP apparatus IV (40%). In terms of f2 
(fig. 3) and D.D.E. (table 2), R2 and the generic products (G1 & G2) 
had similar dissolution profiles with respect to innovator product 
R1, opposing D.C.I. values which revealed dissimilar dissolution 
profiles (table 2). 
From the previous results, it was found that the dissolution profiles 
of the two investigated MH IR innovator products (R1 and R2) were 
similar when USP apparatus II (f2 = 66) and beaker method (f2 = 61) 
were used, while opposite results were found with USP apparatus IV 
(f2 = 48) (fig. 3). Nevertheless, Wong and Ngo [32] reported that 
even if multiple generic MH IR tablets had different dissolution 
profiles in vitro, the in vivo performance might not likely be diverted 
to a clinically significant extent. The previous conclusion was in 
complete accordance with Oyetunde et al. [29] who discussed in 
their study that even if the dissolution performance of BSC class III 
drug products were found to be relatively slow, they may still have 
similar in vivo absorption. 
Our study revealed that the reported MH pharmacopeial dissolution 
test was not discriminating enough, to show minor differences 
between dissolution patterns of different generics (fig. 3). On the 
other hand, USP apparatus IV was more beneficial in the 
Emara et al. 
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development of a much more discriminating dissolution method 
than the pharmacopeial method, similar observations were stated by 
Medina et al. [46] who studied in vitro dissolution profiles of 
carbamazepine IR generic tablet products using different dissolution 
apparatuses (II and IV). In a recent study, similar observation 
regarding USP apparatus IV and II was noticed for marketed 
suspensions of carbamazepine [47]. Again this was in accordance 
with the work done by Gite et al. [51] on atorvastatin using USP 
apparatus I and IV. 
According to USP specifications, the percent of MH dissolved from IR 
tablet products should not be less than 75% of the labeled amount of MH 
in 30 min (Q30 min). It is noticeable from Q30 min values listed above that no 
matter which apparatus was employed, none of MH IR products met the 
requirements of the USP pharmacopeia [37]. Likewise, other researchers 
faced such out of limits results. For example, Hurtado y de la Peña et al. 
[43] reported that for different marketed albendazole products, only the 
reference product and one of the generic products studied met the USP 
specifications. Moreover, Emara et al. [18] presented two commercial 
products of gliclazide that failed to meet the requirements described by 
the British Pharmacopoeia.  
Comparative in vitro release study of MH CR products 
Dissolution profiles of the two MH CR products studied, R3 and G3, 
obtained using USP apparatus II, USP apparatus IV and beaker 
method are shown in fig. 4 (A-C). Regarding MH CR products, the 
amount of drug released in 6 h (Q6h) according to USP specifications 
for MH tablet assay should be between 65-85% of the labeled 
amount of MH [36]. The dissolution results of MH CR commercial 
products (fig. 4: A-C) revealed that the innovator product R3 
(Glucophage XR®) did not meet these USP release criteria. Q6h 
values for R3 were 40.1%, 37.8% and 57.7% obtained by USP 
apparatuses II, IV and beaker method, respectively. On the other 
hand, the generic product G3 (Cidophage Retard®) complied with 
these specifications. 
Fig. 5 displayed a comparison between dissolution profiles of MH CR 
generic product G3 (Cidophage Retard) versus R3 (Glucophage 
XR®) expressed by the similarity factor "ƒ2", utilizing different 
apparatuses. Meanwhile, table 3 listed the mean dissolution 
efficiencies (D. E.) with 95% confidence intervals (C. I.) calculated 
from in vitro release data of MH CR tablets. For all studied 
apparatuses, the dissolution profile of the generic product G3 
(Cidophage Retard®) was dissimilar with the innovator R3 in terms 
of D. D. E., D. C. I. and ƒ2 (table 3 and fig. 5). Thereby, it might not be 
interchangeable with the reference brand. This variability in MH 
release may be due to differences in particle size and/or surface area 
of MH particles, uneven distribution of hydrodynamic force [50] or 








Fig. 5: Comparison between dissolution profiles of G3 generic product (Cidophage Retard) versus R3 (Glucophage XR®) expressed by the 
similarity factor "ƒ2", utilizing different apparatuses (mean±SD, n = 3) 
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Table 3: Mean dissolution efficiencies (D. E.) with 95% confidence intervals (C. I.) calculated from in vitro release data of MH CR tablets 
Apparatus Tested product Product code Mean D. E. (%) with C. I. D. D. E. D. C. I. 
USP 2 Glucophage XR® 1000 mg  R3 27.27 (22.92,31.61) 0 0 
Cidophage Retard® 850 mg  G3 53.04 (50.42,55.67) -25.77 -18.81 
USP 4 Glucophage XR® 1000 mg  R3 25.57 (14.86, 36.28) 0 0 
Cidophage Retard® 850 mg  G3 67.57 (64.27, 70.87) -42 -27.99 
Beaker method Glucophage XR® 1000 mg  R3 37.63 (21.55,53.72) 0 0 
Cidophage Retard® 850 mg  G3 75.45 (55.66,95.25) -37.82 -1.94 
*D. E.: Dissolution Efficiency, C. I.: Confidence Intervals, D. D. E.: Difference of the mean D. E. between the innovator and the tested product, D. C. I.: 
Difference in confidence intervals and is calculated by considering the maximum possible mean D. E. value of Innovator and minimum possible 
mean D. E. value of other products (mean±SD, n = 3). 
 
Despite the possible importance of the effect of different excipients 
on the release profile of MH tablets under test, it could not be 
evaluated because only the innovator product R3 (Glucophage XR®) 
listed the excipients on its pamphlet. In this context, Block et al. and 
Stuart et al. [31, 53] stated that the difference in dissolution profiles 
of products could be attributed to the excipients and/or the 
manufacturing process. Furthermore, Berthelsen et al. [54] reported 
that excipients might disturb the drug-filter interaction/adsorption 
in USP apparatus IV, causing differences in dissolution profiles and 
interfering with the prediction of in vivo data. 
Shaw and Krauss [55] informed that the FDA has not publicized 
safety in generic-to-generic switches, which could possibly cause 
drug concentration deviations up to 40%. Our present study 
involving USP apparatus II and IV and beaker method revealed 
significant differences in the rate of release of MH from Egyptian 
CR generic product investigated as compared to the innovator 
product.  
Although USP apparatus IV can usually discriminate between 
different pharmaceutical products, nevertheless, it has some 
disadvantages as there is always a risk of filter clogging, difficulties 
in confirming the flow rate during testing, and a necessity for a very 
large amount of dissolution medium for open system runs [54]. As a 
result of such possible problems, it might still be better to use the 
Pharmacopeial method (USP apparatus II). 
CONCLUSION 
Data with the flow-through cell apparatus approve that the 
dissolution method proposed has a greater discriminating ability 
compared to USP apparatus II and beaker method to assess 
differences in dissolution profiles of MH market products. Our 
results revealed that the same trade name does not consequently 
indicate that products are pharmaceutically identical. The study 
showed that the dissolution performance of the investigated MH 
market products was questionable, where only the generic CR 
product succeeded to meet the USP dissolution specifications under 
the studied test conditions. On the contrary of MH IR products, 
generic MH CR product showed dissimilar dissolution behavior 
compared to the innovator product. Accordingly, we recommend 
that physicians and pharmacists should generally avoid the 
hypothesis that generic and reference market products are 
therapeutically equivalent and hence could be interchangeable 
safely, even when labeled to contain the same drug substance. It is 
possible to mention that MH products with differences in dissolution 
performance are candidates to show bioavailability differences. 
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